PROGRAM AGENDA
Lee Greenberger, PhD
Chief Scientific Officer, The Leukemia & Lymphoma Society (LLS)
Kenneth Anderson, MD (Chair)
Carl June, MD
Gail Roboz, MD
Louis Staudt, MD, PhD
Kenneth Anderson, MD
Larry Saltzman, MD
All Faculty
FACULTY PANEL
Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, MA
Chief Scientific Officer
The Leukemia & Lymphoma Society
Rye Brook, NY
Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Professor, Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
New York, NY
Executive Research Director
The Leukemia & Lymphoma Society
Rye Brook, NY
Chief, Lymphoid Malignancies Branch
NIH Distinguished Investigator
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD
TARGET AUDIENCE
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
EDUCATIONAL OBJECTIVES
After completing this activity, participants should be better able to:
- Describe the current state of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies
- Identify the impact of minimal residual disease (MRD) analysis and pre-leukemic clones on the treatment of acute leukemia
- Summarize the efficacy of targeted therapy in genetic subtypes of aggressive lymphoma
- Assess how novel therapeutic strategies lead to improved survival in myeloma
- Analyze the impact of COVID-19 and its effect on therapy and outcomes in blood cancer patients
ACCREDITATION
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.RMEI Medical Education, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
FEE INFORMATION
There is no fee for this educational activity.
STATEMENT OF SUPPORT
Funding provided by The Leukemia & Lymphoma Society. No commercial support provided for this accredited continuing education activity.
For information on leukemia, lymphoma, or myeloma, contact an LLS Information Specialist at (800) 955-4572 or infocenter@LLS.org, or visit www.LLS.org.
FOLLOW LLS
